Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

GH

+ Watchlist+ Portfolio

Guardant Health, Inc.

Regulated industrySells to businessesTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$143.28
52-Week Range
$74.55 – $191.05
Market Cap
$19.64B
P/E (TTM)
—
EPS (TTM)
-3.68
Dividend Yield
0.00%
Advanced Metrics
Price/Book
—
PEG Ratio
—
Return on Equity
—
Return on Assets
-19.92%
Gross Margin
65.19%
Operating Margin
-39.40%
Profit Margin
-37.93%
Current Ratio
3.60
Debt/Equity
—
Total Debt
$1.69B
Free Cash Flow
$-60.54M
Revenue Growth
36.10%
Earnings Growth
—
Enterprise Value
$20.30B

Market Snapshot

About

Guardant Health, Inc. is a precision oncology company focused on developing and commercializing blood-based liquid biopsy tests for cancer screening, diagnosis, and treatment monitoring. The company's flagship products include Guardant360, a comprehensive genomic profiling test for advanced cancer patients, and Guardant Reveal for minimal residual disease detection and recurrence monitoring. Guardant's Shield test is a blood-based screening solution for colorectal cancer in average-risk individuals. The company's liquid biopsy platform analyzes circulating tumor DNA (ctDNA) in blood samples, offering a less invasive alternative to traditional tissue biopsies. Guardant Health is at the forefront of precision medicine, partnering with pharmaceutical companies and healthcare providers to improve cancer outcomes.